Editas Medicine Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Editas Medicine de 1.4% y 32.5% por año respectivamente. Se prevé que el BPA crezca en un 9.3% al año. Se espera que la rentabilidad financiera sea de -218.2% en 3 años.

Información clave

1.4%

Tasa de crecimiento de los beneficios

9.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.2%
Tasa de crecimiento de los ingresos	32.5%
Rentabilidad financiera futura	-218.2%
Cobertura de analistas	Good
Última actualización	08 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Dec 28

Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles

Dec 15

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17

Editas: Data Was Eagerly Anticipated But Failed To Impress

Nov 03

Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Sep 07

Editas: Gene Therapy Specialist Leading The Way In Eye Disease

Aug 27

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Aug 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:EDIT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	65	-249	-259	-161	10
12/31/2025	25	-242	-230	-203	16
12/31/2024	34	-206	-194	-190	17
12/31/2023	78	-153	-137	-132	N/A
9/30/2023	25	-195	-156	-152	N/A
6/30/2023	19	-206	-169	-165	N/A
3/31/2023	23	-219	-168	-164	N/A
12/31/2022	20	-220	-181	-177	N/A
9/30/2022	26	-201	-176	-170	N/A
6/30/2022	32	-184	-171	-162	N/A
3/31/2022	26	-186	-174	-164	N/A
12/31/2021	26	-193	-172	-164	N/A
9/30/2021	24	-214	-176	-169	N/A
6/30/2021	81	-167	-189	-183	N/A
3/31/2021	92	-135	-180	-175	N/A
12/31/2020	91	-116	-187	-180	N/A
9/30/2020	92	-91	-106	-99	N/A
6/30/2020	33	-132	-79	-71	N/A
3/31/2020	24	-142	-73	-66	N/A
12/31/2019	21	-134	-47	-41	N/A
9/30/2019	14	-121	-86	-80	N/A
6/30/2019	25	-103	-66	-61	N/A
3/31/2019	30	-108	-57	-52	N/A
12/31/2018	32	-110	-50	-46	N/A
9/30/2018	29	-121	-76	-72	N/A
6/30/2018	21	-132	-96	-92	N/A
3/31/2018	17	-120	-104	-102	N/A
12/31/2017	14	-120	-11	-9	N/A
9/30/2017	11	-124	N/A	2	N/A
6/30/2017	6	-118	N/A	13	N/A
3/31/2017	6	-111	N/A	29	N/A
12/31/2016	6	-97	N/A	-50	N/A
9/30/2016	6	-71	N/A	-45	N/A
6/30/2016	6	-57	N/A	-39	N/A
3/31/2016	2	-86	N/A	-9	N/A
12/31/2015	2	-73	N/A	-5	N/A
9/30/2015	1	-66	N/A	-1	N/A
6/30/2015	0	-62	N/A	9	N/A
3/31/2015	N/A	-17	N/A	-13	N/A
12/31/2014	N/A	-14	N/A	-9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EDIT siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que EDIT siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que EDIT siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (32.5% al año) de EDIT crezcan más rápidamente que los del mercado US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (32.5% al año) de EDIT crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: EDIT se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Editas Medicine Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 49%, EPS downgraded

Consensus revenue estimates increase by 25%

Consensus revenue estimates increase by 21%

Consensus revenue estimates decrease by 13%, EPS upgraded

Consensus revenue estimates increase by 14%

Price target decreased by 8.6% to US$13.06

Recent updates

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine Q2 2022 Earnings Preview

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Baisong Mei joins Editas Medicine as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Consensus revenue estimates fall by 12%

Price target decreased to US$31.21

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Executive VP & Chief Business Officer notifies of intention to sell stock

Editas: The Unforeseen Detrimental Effect Of Patent Win

Editas: CRISPR Gene Editing Biotech With Promising Future

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$37.23

Consensus revenue estimates increase by 15%